Clinical Efficacy of Sanju Kechuan Oral Liquid on Phlegm-turbid Obstruction of Lung Syndrome of Asthma at Acute Episode

Xing CHEN; De-yi YAO; Yun LU; Ming-fei LI

doi:10.13422/j.cnki.syfjx.20192132

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Sanju Kechuan Oral Liquid on Phlegm-turbid Obstruction of Lung Syndrome of Asthma at Acute Episode

Clinic | 更新时间：2021-02-09

- Clinical Efficacy of Sanju Kechuan Oral Liquid on Phlegm-turbid Obstruction of Lung Syndrome of Asthma at Acute Episode
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 4, Pages: 114-119(2020)
- 作者机构：
  
  1.成都中医药大学，成都　 610075
  2.成都中医药大学　附属医院，成都　 610075
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20192132
  CLC： R25; R256; R256.1; R256.12
- Received：27 June 2019，
  
  Published Online：29 July 2019，
  
  Published：20 February 2020
- 稿件说明：
移动端阅览
Xing CHEN, De-yi YAO, Yun LU, et al. Clinical Efficacy of Sanju Kechuan Oral Liquid on Phlegm-turbid Obstruction of Lung Syndrome of Asthma at Acute Episode[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(4): 114-119.
DOI：

Xing CHEN, De-yi YAO, Yun LU, et al. Clinical Efficacy of Sanju Kechuan Oral Liquid on Phlegm-turbid Obstruction of Lung Syndrome of Asthma at Acute Episode[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(4): 114-119. DOI： 10.13422/j.cnki.syfjx.20192132.

摘要

目的：

观察三桔咳喘口服液治疗哮喘急性发作期痰浊阻肺证的临床疗效及对肺功能和炎症因子的影响。

方法：

将117例患者按随机数字表法分为对照组57例和观察组60例。对照组采用布地奈德混悬液吸入剂，1～2 mg/次，2次/d，经雾化器给药；不能控制者，加用沙美特罗替卡松粉吸入剂，50～250 μg/次，早晚各1吸。观察组在对照组治疗的基础上，口服三桔咳喘口服液，20 mL/次，3次/d。两组疗程均为连续治疗7 d。进行治疗前后哮喘急性发作时病情严重程度和痰浊阻肺证评分；记录1 s用力呼气容积(FEV

)和呼气流量峰值昼夜变异率(PEF)；随访4周进行哮喘控制测试(ACT)；记录治疗前后呼出气一氧化氮(FeNO)，外周血和痰液嗜酸粒细胞(Eos)百分比；检测治疗前后外周血白细胞介素-2(IL-2)，IL-4，IL-5，IL-17和干扰素-

(IFN-

)水平。

结果：

观察组疗效好于对照组(

＝1.916，

0.05)；观察组哮喘急性发作时病情严重程度评分和痰浊阻肺证评分均低于对照组(

0.01)；观察组FEV

高于对照组(

0.05)，PEF低于对照组(

0.05)；观察组哮喘控制情况优于对照组(

＝2.231，

0.01)；观察组FeNO，痰液Eos和外周血Eos水平均低于对照组(

0.01)；观察组IFN-

和IL-2水平均高于对照组(

0.01)，IL-4，IL-5，IL-17水平均低于对照组(

0.01)。

结论：

在常规西医治疗的基础上，加用三桔咳喘口服液可明显减轻哮喘急性发作期痰浊阻肺证患者病情严重程度，提高肺功能，控制哮喘发作，并可抑制气道炎症反应，临床疗效优于单纯布地奈德混悬液＋沙美特罗替卡松粉治疗。

Abstract

Objective:

To observe the clinical efficacy of Sanju Kechuan oral liquid on phlegm-turbid obstruction of lung syndrome of asthma at acute episode

in order to study its effect on pulmonary function and inflammatory factors.

Method:

One hundred and seventeen patients were randomly divided into control group (57 cases) and observation group (60 cases) by random number table. Patients in control group got budesonide suspension for inhalation by atomizer

1-2 mg/time

2 times/days. Patients who could not control were added with salmeterol xinafoate and fluticasone propionate powder for inhalation in every morning and evening

50-250 μg/time. In addition to the therapy of control group

patients in observation group was added with Sanju Kechuan oral liquid

20 mL/time

3 times/days. The course of treatment was 7 days. And before and after treatment

the severity of asthma at acute episode and the phlegm-turbid obstruction of lung syndrome were scored. And 1-second forced expiratory volume (FEV

)

diurnal variability of peak expiratory flow (PEF)

fractional exhaled nitric oxide (FeNO)

peripheral blood

percentage of sputum eosinophils (Eos) were recorded

and levels of interleukin-2 (IL-2)

interferon-gamma (IFN-

)

IL-4

IL-5 and IL-17 were detected.

Result:

The clinical efficacy in observation group was better than that in control group (

=1.916

0.05). Scores of severity of asthma at acute episode and phlegm-turbid obstruction of lung syndrome were lower than those in control group (

0.01). And FEV

was higher than that in control group (

0.05)

while PEF was lower than that in control group (

0.05). Asthma control in observation group was better than that in control group (

=2.231

0.01). And levels of FeNO

Eos in sputum

Eos in peripheral blood

IL-4

IL-5 and IL-17 were lower than those in control group (

0.01)

whereas levels of IL-2 and IFN-

were higher than those in control group (

0.01).

Conclusion:

In addition to the therapy of routine western medicine

Sanju Kechuan oral liquid can alleviate the severity of phlegm-turbid obstruction of lung syndrome of asthma at acute episode

improve the lung function

control the attack of asthma and inhibit the airway inflammation

with a better the clinical efficacy than pure western medicine treatment.

关键词

Keywords

references

中华医学会呼吸病学分会哮喘学组．支气管哮喘防治指南(2016版) [J]．中华结核和呼吸杂志， 2016 ， 39 ( 9 )： 675 - 697 .

赵晨曲，杜娟，董亚琼．支气管哮喘的诊治进展 [J]．贵州医药， 2018 ， 42 ( 9 )： 1060 - 1062 .

周松晶，李玉玲，史佳．加味苓甘五味姜辛汤对支气管哮喘慢性持续期痰哮证患者炎症因子的影响 [J]．中国实验方剂学杂志， 2017 ， 23 ( 4 )： 198 - 202 .

中华中医药学会肺系病专业委员会．支气管哮喘中医证候诊断标准(2016版) [J]．中医杂志， 2016 ， 57 ( 22 )： 1978 - 1980 .

杨昆，徐升，王飞，等．从“风痰”论治支气管哮喘的病因病机研究 [J]．中药与临床， 2016 ， 7 ( 5 )： 45 - 46 .

白洋，李涓，程媛．麻桔喘咳口服液临床前基础研究 [J]．中药与临床， 2013 ， 4 ( 1 )： 31 - 33，36 .

赵文，王知兵，卢云，等．麻桔喘咳口服液治疗慢性阻塞性肺疾病急性加重期急诊留观病人疗效观察 [J]．亚太传统医药， 2017 ， 13 ( 2 )： 129 - 132 .

卢云．麻桔喘咳口服液对大鼠实验性肺心病的影响 [J]．中国中医基础医学杂志， 2014 ， 20 ( 4 )： 445 - 447 .

白洋 . 麻桔喘咳口服液在治疗肺心病急性发作期中的研究 [D]．成都：成都中医药大学 . 2013 .

胡海英．影响成人支气管哮喘患者病情控制水平的相关危险因素调查研究 [J]．医药论坛杂志， 2017 ， 38 ( 7 )： 50 - 51，54 .

刘国梁，林江涛，陈萍，等．支气管哮喘对中国患者生活及情感影响及相关因素的调查分析 [J]．中国呼吸与危重监护杂志， 2016 ， 15 ( 3 )： 232 - 235 .

V Giraud , F A Allaert , N Roche ． Inhaler technique and asthma: feasability and acceptability of training by pharmacists [J]． Respirmedicine , 2011 , 105 ( 12 )： 1851 - 1822 .

乔丽萍． β 2 受体激动剂在支气管哮喘治疗中的合理应用 [J]．首都食品与医药， 2017 ， 24 ( 14 )： 72 - 73 .

李宣霖，马锦地，李建生，等．现代名老中医诊治支气管哮喘文献证候分析 [J]．中医杂志， 2017 ， 58 ( 16 )： 1416 - 1420 .

曹玉雪，董竞成，杜懿杰，等．支气管哮喘“寒痰”与“热痰”证型微观辨证指标及其炎症特点 [J]．中国中西医结合杂志， 2010 ， 30 ( 8 )： 828 - 832 .

杨昕宇，肖长芳，张凯熠，等．麻黄临床应用与药理作用研究进展 [J]．中华中医药学刊， 2015 ， 33 ( 12 )： 2874 - 2877 .

李露，戴婷，李小龙，等．苦杏仁苷药理作用的研究进展 [J]．吉林医药学院学报， 2016 ， 37 ( 1 )： 63 - 66 .

李想，李冀．甘草提取物活性成分药理作用研究进展 [J]．江苏中医药， 2019 ， 51 ( 5 )： 81 - 86 .

陈志营．呼出气一氧化氮测定对支气管哮喘-慢性阻塞性肺疾病重叠综合征患者的诊断价值 [J]．检验医学与临床， 2018 ， 15 ( 18 )： 2803 - 2805 .

韩君萍，李双，赵叶，等．支气管哮喘气道炎症发病机制及针刺调节的研究进展 [J]．中国民族民间医药， 2016 ， 25 ( 22 )： 19 - 23 .

颜玺，郭亚蕾，薛中峰．苍耳子挥发油对支气管哮喘大鼠气道重塑的影响 [J]．中国实验方剂学杂志， 2019 ， 25 ( 14 )： 106 - 111 .

高阳，杨帆．支气管哮喘患者外周血Th1，Th2与Th17细胞表达水平及临床意义 [J]．解放军医药杂志， 2017 ， 29 ( 1 )： 76 - 79 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guben Pingchuan Decoction Treatment on 48 Cases of Chronicity-persistent Period in Bronchial Asthma

Effect of Clinical Efficacy, Lung Function and Inflammatory Cytokines of Reduning Injection Combined with Salmeterol and Fluticasone Propionate Inhalation Powder for Patients with Bronchial Asthma

Guben Fangxiao decoction Regulates Expression of CGRP /ILC2 and GABA in Human Bronchial Epithelial Cells Stimulated with IL-4 Combined with IL-13

Research Progress on Pathogenesis of Ankylosing Spondylitis and Intervention of Traditional Chinese Medicine： A Review

Yiqi Wenyang Huwei Decoction in Treatment of Bronchial Asthma in Rats by Regulating TGF-β₁/Smad3 Signaling Pathway

Related Author

HUANG Bo

LI Tian-yu

QIN Jian-ping

WANG Yu-he

DENG Jun

LIANG Yu-jia

LIU Chun-feng

XIONG Ying

Related Institution

The First Clinical Medical College of Nanjing University of Chinese Medicine

Affiliated Hospital of Nanjing University of Chinese Medicine

Gansu Provincial Hospital of TCM Rheumatism Osteopathy Center

Gansu University of Traditional Chinese Medicine （TCM）

Jiangxi University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰